menu

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

Be part of the knowledge.
Register

ReachMD is even better when
you join the community!
Registration is free and easy.

Register Now

FDA D.I.S.C.O.: Rucaparib in Ovarian Cancer

    FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with advanced ovarian cancer.
    • Overview

      FDA medical oncologists discuss the agency’s accelerated approval of rucaparib for treatment of patients with deleterious BRCA mutation-associated advanced ovarian cancer who have been treated with two or more chemotherapies.

      Released May 17, 2017

    Facebook Comments

    You must be in to display playlists.

    Get a Dose of ReachMD in Your Inbox
    and Practice Smarter Medicine

    Stay current with the best in medical education.